MX2022005345A - Terapia de combinación para el tratamiento de cáncer cerebral. - Google Patents

Terapia de combinación para el tratamiento de cáncer cerebral.

Info

Publication number
MX2022005345A
MX2022005345A MX2022005345A MX2022005345A MX2022005345A MX 2022005345 A MX2022005345 A MX 2022005345A MX 2022005345 A MX2022005345 A MX 2022005345A MX 2022005345 A MX2022005345 A MX 2022005345A MX 2022005345 A MX2022005345 A MX 2022005345A
Authority
MX
Mexico
Prior art keywords
methods
compositions
brain cancer
certain embodiments
combination therapy
Prior art date
Application number
MX2022005345A
Other languages
English (en)
Inventor
Jian Yan
Israel Lowy
Bernadette Ferraro
Jewell Walters
Amy- Lee Bredlau
Jeffrey Skolnik
Original Assignee
Inovio Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inovio Pharmaceuticals Inc filed Critical Inovio Pharmaceuticals Inc
Publication of MX2022005345A publication Critical patent/MX2022005345A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001136—Cytokines
    • A61K39/001142—Chemokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A61K39/001195—Prostate specific membrane antigen [PSMA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001152—Transcription factors, e.g. SOX or c-MYC
    • A61K39/001153—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001157—Telomerase or TERT [telomerase reverse transcriptase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55538—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092—Details
    • A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy

Abstract

En la presente se proporcionan moléculas de ácido nucleico, proteínas, composiciones y métodos para tratar cáncer cerebral en un sujeto. En algunas modalidades, las composiciones comprenden antígenos de cáncer hTERT, WT-1 y PSMA. En algunas modalidades, las composiciones también comprenden un adyuvante. Los métodos comprenden administrar a un sujeto que lo necesita los antígenos de cáncer. De acuerdo con determinadas modalidades, los métodos implican además administrar el adyuvante y un anticuerpo anti-PD-1. En determinadas modalidades, los métodos comprenden además administrar radioterapia y/o un agente quimioterapéutico. En determinadas modalidades, los métodos han demostrado ser clínicamente seguros, clínicamente eficaces, o ambos.
MX2022005345A 2019-11-04 2020-11-04 Terapia de combinación para el tratamiento de cáncer cerebral. MX2022005345A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962930417P 2019-11-04 2019-11-04
US202062988102P 2020-03-11 2020-03-11
US202063018060P 2020-04-30 2020-04-30
US202063070987P 2020-08-27 2020-08-27
PCT/US2020/058891 WO2021092019A1 (en) 2019-11-04 2020-11-04 Combination therapy to treat brain cancer

Publications (1)

Publication Number Publication Date
MX2022005345A true MX2022005345A (es) 2022-08-11

Family

ID=75686760

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022005345A MX2022005345A (es) 2019-11-04 2020-11-04 Terapia de combinación para el tratamiento de cáncer cerebral.

Country Status (12)

Country Link
US (1) US20210128710A1 (es)
EP (1) EP4055033A4 (es)
JP (1) JP2023500337A (es)
KR (1) KR20220097928A (es)
CN (1) CN114901677A (es)
AU (1) AU2020380288B2 (es)
BR (1) BR112022008164A2 (es)
CA (1) CA3156227A1 (es)
CO (1) CO2022007361A2 (es)
IL (1) IL292462A (es)
MX (1) MX2022005345A (es)
WO (1) WO2021092019A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113447654B (zh) * 2021-07-15 2022-03-22 广州济士源生物技术有限公司 质谱技术检测尿液中psm-e分子水平在制备用于早期诊断***癌产品中的应用
IL310808A (en) * 2021-08-13 2024-04-01 Inovio Pharmaceuticals Inc Combined therapy for the treatment of brain cancer
US11526994B1 (en) * 2021-09-10 2022-12-13 Neosoma, Inc. Labeling, visualization, and volumetric quantification of high-grade brain glioma from MRI images

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7833754B2 (en) * 2006-01-13 2010-11-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services IL-12 for expression in mammalian cell
HUE050787T2 (hu) * 2013-02-26 2021-01-28 Memorial Sloan Kettering Cancer Center Immunterápiás készítmények és eljárások
TWI681969B (zh) * 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
CA3014001A1 (en) * 2016-02-25 2017-08-31 Cell Medica Switzerland Ag Binding members to pd-l1
EP3497208A4 (en) * 2016-08-09 2020-03-11 Turnstone Limited Partnership ONCOLYTIC RHABDOVIRUS EXPRESSING IL12
WO2018064588A2 (en) * 2016-09-30 2018-04-05 Weiner, David Tert immunogenic compositions and methods of treatment using the same
EA201990624A1 (ru) * 2017-03-07 2019-09-30 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Иммуногенные композиции tert и способы лечения с их использованием
US11603407B2 (en) * 2017-04-06 2023-03-14 Regeneron Pharmaceuticals, Inc. Stable antibody formulation
US11253608B2 (en) * 2017-05-26 2022-02-22 Epicentrx, Inc. Recombinant adenoviruses carrying transgenes
CN109486828B (zh) * 2018-12-27 2022-05-31 广东暨大基因药物工程研究中心有限公司 一种编码重组人白细胞介素12的基因及其应用
BR112021021713A2 (pt) * 2019-05-13 2022-04-19 Regeneron Pharma Método de tratamento de câncer ou inibição do crescimento de um tumor
WO2021051065A1 (en) * 2019-09-12 2021-03-18 Inovio Pharmaceuticals, Inc. Tert, wt-1, pmsa immunogenic compositions and methods of treatment using the same
CN114599392A (zh) * 2019-10-31 2022-06-07 四十七公司 基于抗cd47和抗cd20的血癌治疗

Also Published As

Publication number Publication date
BR112022008164A2 (pt) 2022-07-12
WO2021092019A1 (en) 2021-05-14
CN114901677A (zh) 2022-08-12
CA3156227A1 (en) 2021-05-14
EP4055033A4 (en) 2023-12-06
IL292462A (en) 2022-06-01
US20210128710A1 (en) 2021-05-06
EP4055033A1 (en) 2022-09-14
JP2023500337A (ja) 2023-01-05
AU2020380288B2 (en) 2024-02-01
AU2020380288A1 (en) 2022-06-16
KR20220097928A (ko) 2022-07-08
CO2022007361A2 (es) 2022-06-10

Similar Documents

Publication Publication Date Title
MX2022005345A (es) Terapia de combinación para el tratamiento de cáncer cerebral.
CY1124791T1 (el) Μορια δεσμευσης ειδικα για cd73 και χρησεις αυτων
MX2020001996A (es) Moleculas anti-cd137 y uso de estas.
PH12019501663A1 (en) Anti-gpr20 antibody and anti-gpr20 antibody-drug conjugate
MX2021013830A (es) Inhibidores de ezh2 para tratar linfomas.
BR112019021822A2 (pt) Terapia de combinação
MX2018013848A (es) Combinacion de anticuerpos anti-pd-1s y radiacion para tratar cancer.
MX2019009468A (es) Proteínas de unión multiespecíficas para la activación de células asesinas naturales y usos terapéuticos de las mismas para tratar cáncer.
MX2019011148A (es) Metodos de tratamiento.
BR112016005303A2 (pt) anticorpos anti-b7-h1 para tratamento de tumores
EA201291195A1 (ru) Усовершенствованная терапия рака на основе опухолеассоциированных антигенов, полученных из циклина d1
NZ756820A (en) Methods and compositions for treating cancers using antisense
PH12021551036A1 (en) Anti-liv1 immune cell cancer therapy
PH12015502260A1 (en) C. novyi for the treatment of solid tumors in humans
MX2019003722A (es) Composiciones inmunogénicas de tert y métodos de tratamiento que las utilizan.
PH12021551047A1 (en) Anti-ptk7 immune cell cancer therapy
WO2019112978A3 (en) Anti-dclk1 antibodies and chimeric antigen receptors, and compositions and methods of use thereof
PH12021550376A1 (en) Combination therapy
MX2021003262A (es) Metodos de tratamiento.
BR112016023011A2 (pt) tratamento de câncer gástrico
MX2020001287A (es) Receptor de linfocitos t (tcrs) especificos de braf y usos de los mismos.
EA201491352A1 (ru) Способ лечения рака груди
BR112019005825A2 (pt) vírus envelopado modificado, composição farmacêutica, e, método para tratar um câncer
MX2021003265A (es) Metodos de tratamiento.
MX2017013666A (es) Terapia de combinacion de agente anti-fuctactico y agente de inmunoterapia y composiciones para el tratamiento de cancer.